Dear HIFA colleagues,
We are pleased to announce that applications for inclusion in the next revision of the WHO Model List of Essential Medicines have now been published here and are open for public review and comment. https://www.who.int/groups/expert-committee-on-selection-and-use-of-esse...
The meeting of the 23rd WHO Expert Committee on the Selection and Use of Essential Medicines will be coordinated from WHO Headquarters, Geneva and held virtually on 21 June to 2 July 2021 to revise and update the WHO Model List of Essential Medicines (EML) and the WHO Model List of Essential Medicines for Children (EMLc). During the meeting the Expert Committee will consider the applications along with accompanying comments.
The Secretariat welcomes comments that offer their perspective on the applications that includes additional evidence of: clinical efficacy and safety, public health relevance, consideration of cost and cost effectiveness, feasibility of implementation, and relevant perspectives from a country experience. Where relevant, data sources should be appropriately referenced.
Interested stakeholders are invited to submit comments on the applications to the Secretary of the Expert Committee, Dr Benedikt Huttner, via email to email@example.com. Comments must be provided in PDF format, and the file name should clearly reference the application to which they apply. All comments received will be published on this webpage and will be provided to the Expert Committee for their consideration. The deadline for submission of comments is 21 May 2021.
Expert Committee on the Selection and Use of Essential Medicines
Medicines Selection, IP and Affordability (MIA)
Department of Health Products Policy and Standards (HPS)
20 Avenue Appia
CH-1211 Geneva 27
Dr Lorenzo Moja
Secretariat of the Model List of Essential Medicines
Department of Health Products Policy and Standards
World Health Organization
Office: +41 (0)22 791 3756
Mobile: +41 (0)79 506 9223
Follow WHO on Facebook, Twitter, YouTube, Instagram
HIFA profile: Lorenzo Moja works in the Department of Essential Medicines and Health Products, World Health Organization, Geneva. mojal AT who.int